Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13853481 | 0.65 | ALDH1A1 (0.61) | ALDH1A1KDM4EL3MBTL1TSHR | |
| SCHEMBL13853482 | 0.62 | MAPT (0.54) | ALDH1A1KDM4EL3MBTL1TSHR | |
| SCHEMBL10145466 | 0.61 | HDAC1 (0.38) | ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL17037052 | 0.58 | RAB9A (0.40) | L3MBTL1 | |
| SCHEMBL13870663 | 0.56 | HTT (0.60) | ALDH1A1 | |
| SCHEMBL13870634 | 0.56 | SMN1; SMN2 (0.46) | ALDH1A1KDM4ETSHR | |
| SCHEMBL23847789 | 0.56 | NAMPT (0.58) | ALDH1A1KDM4E | |
| SCHEMBL969258 | 0.56 | SMN1; SMN2 (0.67) | ALDH1A1L3MBTL1TSHR | |
| SCHEMBL9269432 | 0.56 | ANPEP (0.58) | ALDH1A1 | |
| SCHEMBL31742336 | 0.56 | L3MBTL1 (0.43) | ALDH1A1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170165263-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2017-06-15 | — | — | US | disclosed |
| US-9533954-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2017-01-03 | — | — | US | disclosed |
| US-20140243308-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8754114-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2014-06-17 | — | — | US | disclosed |
| US-20120165305-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165305-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | TGFBR1 188/4885ALDH1A1 756/4885KDM4E 668/4885 |
| US-20170165263-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | TGFBR1 188/4885ALDH1A1 756/4885KDM4E 668/4885 |
| US-20140243308-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | TGFBR1 188/4885ALDH1A1 756/4885KDM4E 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.